This website uses cookies. By continuing to use this website, you consent to our use of these cookies. Read more about our use of cookies.
we care about rare disease patients
Sobi is dedicated to developing and delivering innovative therapies to improve the lives of rare disease patients.
North America News
FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)
Our Products
Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.
Join Our Team!
At Sobi, it's not about numbers, it's about people. We are small but mighty, as are the rare disease communities we serve.
Sobi United States Office
890 Winter Street
Waltham, MA 02451, USA
Sobi Canada Office
1155 North Service Rd. West, Unit #11
Oakville, Ontario, Canada L6M 3E3
we care about rare disease patients
Sobi is dedicated to developing and delivering innovative therapies to improve the lives of rare disease patients.
North America News
FDA Approves Gamifant® (emapalumab-lzsg), the First and Only Treatment Indicated for Primary Hemophagocytic Lymphohistiocytosis (HLH)
Our Products
Sobi’s product portfolio is primarily focused on inflammation and genetic diseases.
Join Our Team!
At Sobi, it's not about numbers, it's about people. We are small but mighty, as are the rare disease communities we serve.
Sobi United States Office
890 Winter Street
Waltham, MA 02451, USA
Sobi Canada Office
1155 North Service Rd. West, Unit #11
Oakville, Ontario, Canada L6M 3E3